BigHat Biosciences Stock
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
Sign up today and learn more about BigHat Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About BigHat Biosciences Stock
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Investors
Andreessen Horowitz
Lyft, Robinhood, Databricks, Airbnb, Instacart, Stripe, Magic Leap, Rappi, CoinSwitch Kuber, Devoted Health
8VC
Anduril Industries, Sila Nanotechnologies, Cityblock Health, project44, Blend, Aspiration, Addepar, Illumio, BlueVoyant, Guardant Health
Section 32
Celularity, Freenome, Dialpad, Lime, Metromile, Primer, Vineti, Kobalt, BigHat Biosciences
Funding History
December 2019 | $5.3M |
---|---|
February 2021 | $19.0M |
Management
Co-Founder and CEO
Mark DePristo
Co-Founder and CSO
Peyton Greenside
Chief Business Officer
Liz Schwarzbach
Vice President Of Engineering
Ed Abrams
Board of Director
Vineeta Agarwala
Director Board of Directors
Francisco Gimenez
Founding Advisor
Theresa Tribble
Press
pharmtech - Mar, 3 2024
AbbVie Collaborates with BigHat Biosciences on Next-Gen Therapeutic Antibodiesgenengnews - Feb, 17 2024
AI-Created Antibodies Drive Innovation at BigHat Biosciencesbioworld - Jan, 31 2024
Insilico inches closer to claiming title of first generative AI drug ...stocknews - Jan, 31 2024
ABBV: Analyzing December Profit Potential for the Top 4 ...globallegalchronicle - Dec, 19 2023
BigHat Biosciences’ Research Collaboration with AbbVie